Acrivon Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Acrivon Therapeutics, Inc. (ACRV) had Debt Securities, Available-for-sale, Unrealized Loss Position of $0 as of 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-03-19
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $0.00.
- 2025-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $0.00.
- 2024-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $0.00.
- 2024-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $0.00.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-19 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 |
| 2024-12-31 | $0.00 10-K · filed 2025-03-27 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |